Scalper1 News
The FDA approved Pharmacyclics’ (PCYC) Imbruvica for chronic lymphocytic leukemia early Wednesday afternoon, abruptly sending the stock up nearly 7% on the stock market today. Pharmacyclis and its partner, Johnson & Johnson (JNJ) unit Janssen Biotech, said the agency had approved the product to treat the deadly blood cancer in patients who’d received at least one prior therapy. It’s the second indication for Imbruvica, which was launched back in Scalper1 News
Scalper1 News